Ebola vaccines arrive in Uganda for trials
The World Health Organization donated the vaccine to the Ugandan government; it was produced by the Sabin Institute in the US. In human trials, its safety has already been established.
Boakyewaa Lawrencia 
1,200 experimental vaccine doses against the Sudan strain of the Ebola virus have been shipped to Uganda for use in clinical trials.
Since the country announced an Ebola outbreak in September, 142 cases of the Sudan strain have been confirmed, along with 55 fatalities.
There isn't a vaccine available right now that has been shown to work against this particular strain of viral hemorrhagic fever.
In a process known as "ring vaccination," the vaccine will be given to individuals who have come into contact with those who tested positive for the virus.
In order to conduct the study, a group of Ugandan scientists hope to enlist at least 3,000 participants who are six years of age or older.
The World Health Organization donated the vaccine to the Ugandan government; it was produced by the Sabin Institute in the US. In human trials, its safety has already been established.
Since November 30, there haven't been any additional confirmed cases in Uganda, and the last patient to be admitted was discharged on that day.
There have been worries that Uganda's outbreak may be nearing its end when the vaccine doses arrived.
But according to Health Minister Dr. Jane Ruth Aceng, the study is still required to give the nation the public health resources it needs to combat future outbreaks of a similar nature.
